<DOC>
	<DOCNO>NCT00085735</DOCNO>
	<brief_summary>This randomized phase III trial study well standard-dose radiation therapy work compare reduced-dose radiation therapy child 3-7 year age AND well standard volume boost radiation therapy work compare small volume boost radiation therapy give together chemotherapy treat young patient undergone surgery newly diagnose standard-risk medulloblastoma . Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy , vincristine , cisplatin , lomustine , cyclophosphamide , work different way stop tumor cell divide stop grow die . Giving radiation therapy chemotherapy surgery may kill remain tumor cell . It yet know whether standard-dose radiation therapy effective reduced-dose radiation therapy give together chemotherapy surgery treat young patient medulloblastoma .</brief_summary>
	<brief_title>Comparison Radiation Therapy Regimens Combination With Chemotherapy Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare event-free survival ( EFS ) pediatric patient ( 3 7 year age ) newly diagnose standard-risk medulloblastoma treat standard-dose versus ( vs. ) reduced-dose craniospinal radiotherapy ( SDCSI vs. LDCSI ) . II . Compare EFS patient ( 3-21 year age ) treat standard-dose craniospinal radiotherapy posterior fossa boost vs tumor bed boost radiotherapy combination chemotherapy regimen . SECONDARY OBJECTIVES : I . Compare overall survival ( OS ) pediatric patient ( 3-7 year age ) newly diagnose standard-risk medulloblastoma treat SDCSI vs. LDCSI . II . Compare OS patient ( 3-21 year age ) newly diagnose standard-risk medulloblastoma treat PFRT vs. IFRT . III . To evaluate pattern failure patient treated irradiation boost volume small conventional posterior fossa volume . IV . To reduce cognitive , auditory , endocrinologic effect treatment average-risk medulloblastoma reduce dose craniospinal irradiation therapy . V. To determine audiologic endocrinologic toxicity reduce use limited tumor boost volume irradiation compare patient treat conventional target volume radiation . VI . Develop optimal gene expression medulloblastoma outcome predictor , validate prospectively multi-institution randomized clinical trial . VII . To improve compliance long-term quality life ( QoL ) functional status data submission educate institutional nurse administer submit analysis battery four instrument ( Behavior Assessment System Children- 2nd Edition ( BASC-2 ) , Adaptive Behavior Assessment System - 2nd Edition ( ABAS-II ) , Behavior Rating Inventory Executive Function ( BRIEF ) PedsQLTM 4.0 ) . OUTLINE : Patients 3-7 year age randomize 1 4 arm ( Arm I-IV ) . Patients 8-21 year age randomize 1 2 arm ( Arm V VI ) . Within 31 day definitive surgery , patient begin therapy . Patients undergo radiation therapy dose accord Arm randomization day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 ( week 0-6 ) . All patient receive vincristine intravenously ( IV ) 1 minute ( infusion via minibag per institutional policy ) day 8 , 15 , 22 , 29 , 36 , 43 ( week 1-6 ) . ARM I : Patients 3-7 year age undergo lower dose craniospinal irradiation ( LDCSI ) involved-field radiation therapy ( IFRT ) boost . ARM II : Patients 3-7 year age undergo LDCSI whole posterior fossa radiation therapy ( PFRT ) boost . ARM III : Patients 3-7 year age undergo standard dose craniospinal irradiation ( SDCSI ) IFRT boost . ARM IV : Patients 3-7 year age undergo SDCSI PFRT boost . ARM V : Patients 8-21 year age undergo SDCSI IFRT boost . ARM VI : Patients 8-21 year age undergo SDCSI PFRT boost . MAINTENANCE CHEMOTHERAPY : Beginning 4 week completion chemoradiotherapy , patient receive 2 different regimen maintenance chemotherapy total 9 course . Each course regimen A 6 week ( 42 day ) duration . Each course regimen B 4 week ( 28 day ) duration . REGIMEN A ( course 1 , 2 , 4 , 5 , 7 , 8 ) : Patients receive lomustine orally cisplatin IV 6 hour day 1 vincristine IV day 1 , 8 , 15 week 11 , 17 , 27 , 33 , 43 , 49 . REGIMEN B ( course 3 , 6 , 9 ) : Patients receive cyclophosphamide IV 1 hour day 1 2 vincristine IV day 1 8 week 23 , 39 , 55 . Treatment continue absence disease progression unacceptable toxicity . Quality life assess 3-6 month completion radiotherapy 3-4 year study entry . Neurocognitive function may also assess . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Histologically confirm medulloblastoma locate posterior fossa Standardrisk disease Minimal volume , nondisseminated disease , define follow : Residual tumor ≤ 1.5 cm^2 confirm MRI contrast imaging within 21 day surgery No metastatic disease head , spine , cerebrospinal fluid ( CSF ) confirm follow : Enhanced MRI spine within 5 day surgery OR within 28 day surgery Negative cytological examination CSF surgery , study enrollment Brain stem involvement allow Performance status Karnofsky 50100 % ( &gt; 16 year age ) Performance status Lansky 30100 % ( ≤ 16 year age ) Absolute neutrophil count &gt; 1,500/uL Platelet count &gt; 100,000/uL ( transfusion independent ) Hemoglobin &gt; 10 g/dL ( transfusion allow ) Bilirubin &lt; 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 1.5 time ULN age Creatinine clearance OR radioisotope glomerular filtration rate &gt; = 70 mL/min/1.73m^2 serum creatinine base age/gender follow : Age Maximum Serum Creatine ( mg/dL ) 1month &lt; 6 month male : 0.4 female : 0.4 6 month &lt; 1 year male : 0.5 female : 0.5 1 year &lt; 2 year male : 0.6 female : 0.6 2 &lt; 6 year male : 0.8 female : 0.8 6 &lt; 10 year male : 1 female : 1 10 &lt; 13 year male : 1.2 female : 1.2 13 &lt; 16 year male : 1.5 female : 1.4 &gt; = 16 year male : 1.7 female : 1.4 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior chemotherapy Prior corticosteroid allow No prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>